These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22719213)

  • 1. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.
    Fragoulakis V; Kourlaba G; Maniadakis N
    Clinicoecon Outcomes Res; 2012; 4():135-43. PubMed ID: 22719213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.
    Gandhi SK; Jensen MM; Fox KM; Smolen L; Olsson AG; Paulsson T
    Clinicoecon Outcomes Res; 2012; 4():1-11. PubMed ID: 22347800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.
    Pinto CG; Carrageta MO; Miguel LS
    Value Health; 2008; 11(2):154-9. PubMed ID: 18380628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
    Bener A; Dogan M; Barakat L; Al-Hamaq AO
    J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Montouchet C; Ruff L; Balu S
    J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
    Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
    Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
    Ara R; Pandor A; Stevens J; Rees A; Rafia R
    Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia.
    Mould-Quevedo JF; Gutiérrez-Ardila MV; Ordóñez Molina JE; Pinsky B; Vargas Zea N
    Value Health Reg Issues; 2014 Dec; 5():48-57. PubMed ID: 29702787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
    Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
    J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
    Wagner M; Lindgren P; Merikle E; Goetghebeur M; Jönsson B
    Can J Cardiol; 2009 Nov; 25(11):e362-9. PubMed ID: 19898698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.